Key result
In AF patients undergoing PCI with a high thrombotic risk score (≥5), triple antithrombotic therapy reduced the composite of MI and ST compared to double therapy.
Why the study?
Guidelines recommend triple antithrombotic therapy for up to one month in AF patients undergoing PCI at high thrombotic risk, but how to select these high-risk patients remains unclear.
Does triple antithrombotic therapy reduce ischaemic events compared to double antithrombotic therapy in high-risk patients with atrial fibrillation undergoing percutaneous coronary intervention?
Observational
Does triple antithrombotic therapy reduce ischaemic events compared to double antithrombotic therapy in high-risk patients with atrial fibrillation undergoing percutaneous coronary intervention?
A novel 6-variable risk score identifies a small subset of AF patients undergoing PCI (score ≥5) who derive ischaemic benefit from triple antithrombotic therapy without excess bleeding.
Answers are grounded in this paper and cite their sources.
May support TAT in small high-risk subgroup per novel score; hypothesis-generating, requires prospective validation.
BACKGROUND: Current guidelines recommend treating atrial fibrillation (AF) patients who undergo percutaneous coronary intervention (PCI) with triple antithrombotic therapy (TAT) for up to one month in patients at high thrombotic risk. It is unclear how to select these high-risk patients. AIMS: To identify patients at high thrombotic risk who might benefit from TAT over double antithrombotic therapy (DAT). METHODS: This study was a post hoc subanalysis of the RE-DUAL PCI trial. A Cox proportional hazards model was built by stepwise selection of plausible predictor variables for a composite ischaemic endpoint, defined as cardiovascular death, myocardial infarction (MI), stent thrombosis (ST) or ischaemic stroke. The effect of TAT versus DAT was calculated for those patients in the highest proportion of predicted thrombotic risk. A simplified risk score was constructed based on beta-coefficients. RESULTS: For 209 patients (7.7%) the composite ischaemic endpoint occurred during the first year. The simplified risk score contained six variables. In patients with a score ≥5 (n=154, 5.7%), a significant reduction in the composite of MI and ST was observed with TAT versus DAT (6.3% vs 21.0%, p=0.041), without a penalty in terms of bleeding. In patients at low thrombotic risk, a significant increase in bleeding was observed without a reduction of ischaemic events. CONCLUSIONS: Our findings support the use of DAT in the majority of patients. A small subgroup of patients might benefit from TAT and we propose a novel clinical risk score to select these patients.
No takes yet. Share an insight, caveat, or question.
Zwart et al. (2022) conducted an observational in Atrial fibrillation undergoing percutaneous coronary intervention. Triple antithrombotic therapy (TAT) vs. Double antithrombotic therapy (DAT) was evaluated on Composite of myocardial infarction and stent thrombosis in patients with risk score ≥5 (p=0.041). In AF patients undergoing PCI with a high thrombotic risk score (≥5), triple antithrombotic therapy reduced the composite of MI and ST compared to double therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: